TW527354B - Crystalline forms of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4dichlorophenyl)piperidine-3-y1]prop-1-y1]-4-phenyl piperidine-4-y1]-N-methyl acetamide (osanetant) and a process for preparing them - Google Patents

Crystalline forms of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4dichlorophenyl)piperidine-3-y1]prop-1-y1]-4-phenyl piperidine-4-y1]-N-methyl acetamide (osanetant) and a process for preparing them Download PDF

Info

Publication number
TW527354B
TW527354B TW088113235A TW88113235A TW527354B TW 527354 B TW527354 B TW 527354B TW 088113235 A TW088113235 A TW 088113235A TW 88113235 A TW88113235 A TW 88113235A TW 527354 B TW527354 B TW 527354B
Authority
TW
Taiwan
Prior art keywords
oxatin
patent application
scope
temperature
crystalline form
Prior art date
Application number
TW088113235A
Other languages
English (en)
Inventor
Alain Alcade
Gilles Anne-Archard
Patrick Groslclaude
Olivier Monnier
Jerome Roche
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of TW527354B publication Critical patent/TW527354B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

527354 案號88113235 年月日 修正
O:\59\59659.ptc 第23頁

Claims (1)

  1. 527351
    113235 月 a 修正 六、申請專利範圍 」 1 · 一種結晶奥沙田（〇 s a n c t a n t)-結晶型I之方法，其特 徵在於奥沙田於乙醇中之溶液中加入水，然後加熱其至溫 度為6 0 t：至75 t ，然後冷卻至2〇。〇至25 t，然後開始結晶 作用或等至第1個結晶出現，然後增加溫度至4 5 - 5 0 t ，然 後冷卻至〇 t並保持此溫度。 … 2 ·—種結晶奥沙田-結晶型I之方法，其特徵在於將水加 。至奥沙田於乙醇中之溶液，然後加熱其至溫度為6 〇。〇至7 5 ’然後冷卻至4 0 °C，開始結晶作用，繼續冷卻至2 〇 - 2 5 c ’加熱該形成之奥沙田懸浮液至4 5 - 5 0 °C，然後冷卻至 2 0 - 2 5 〇C。
    、3 · 一種結晶奥沙田-結晶型I之方法，其特徵在於加熱奥 沙田於異丙醇中之溶液至溫度6 〇 _ 8 〇。〇，然後冷卻至溫度 。介於0和5 0 t：，然後開始結晶作用；該混合物然後冷卻至〇 C，保持此溫度。 4 · 一種結晶奥沙田-結晶型I丨之方法，其特徵在於加入 異丙基醚與水至奥沙田於乙醇中之溶液，然後於回流下加 熱，然後冷卻。
    5 · —種結晶奥沙田-結晶型丨丨之方法，其特徵在於回流 加熱奥沙田於乙醇/異丙基醚之混合物之溶液，加入異丙 基趟與水，使其冷卻至4 〇 - 5 〇，然後開始結晶作用或等 至第一個結晶出現於冷卻至2 〇 一 2 5 t之前。 6 ·根據申請專利範圍第1至5項中任一項之方法，其特徵 在於結晶出之奥沙田係經中和其苯石黃酸鹽以製得。 7 · —種奥沙田-結晶型I ，其特徵在於其顯示：
    527354 _案號88113235 年/月 日 修正_^ 六、申請專利範圍 -具有最大峰值為1 4 3. 6 ± 0 . 5 °C之熔點 - 68.5±0.5J /克之炫化熱函 - 其粉末X-ray繞射圖顯示17.81 ° 、11.04°與16. 84° 之Bragg 2 (9射線之特性。 8 ·根據申請專利範圍第7項之奥沙田-結晶型I ，其可由 根據申請專利範圍第1至3項中任一項之方法而製得。 9 · 一種奥沙田-結晶型I I ，其特徵在於其顯示： -具有最大峰值為141. 8± 0.5 °C之熔點 - 65.5±0.5J /克之炫化熱函 - 其粉末X-ray繞射圖顯示18.35° 、18. 58°與18.97° 之B r a g g 2 0射線之特性。 1 0 .根據申請專利範圍第9項之奥沙田-結晶型I I ，其可 由根據申請專利範圍第4或5項之方法而製得。 1 1 . 一種用作NK-3拮抗劑之醫藥組合物，其包括根據申 請專利範圍第7至1 0項中任一項之化合物做為活性主成 份。 1 2 .根據申請專利範圍第1 1項之醫藥組合物，其特徵在 於其劑量單位之形式包含0. 5至5 0 0毫克之活性主成份。 1 3.根據申請專利範圍第1 2項之醫藥組合物，其特徵在 於該劑量單位包含介於1至2 5 0毫克之活性主成份。
    O:\59\59659-920103.ptc 第25頁
TW088113235A 1998-08-05 1999-08-04 Crystalline forms of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4dichlorophenyl)piperidine-3-y1]prop-1-y1]-4-phenyl piperidine-4-y1]-N-methyl acetamide (osanetant) and a process for preparing them TW527354B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9810107A FR2782082B3 (fr) 1998-08-05 1998-08-05 Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose

Publications (1)

Publication Number Publication Date
TW527354B true TW527354B (en) 2003-04-11

Family

ID=9529458

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088113235A TW527354B (en) 1998-08-05 1999-08-04 Crystalline forms of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4dichlorophenyl)piperidine-3-y1]prop-1-y1]-4-phenyl piperidine-4-y1]-N-methyl acetamide (osanetant) and a process for preparing them

Country Status (32)

Country Link
US (1) US7041679B2 (zh)
EP (1) EP1102747B1 (zh)
JP (1) JP3807938B2 (zh)
KR (1) KR100571944B1 (zh)
CN (1) CN1114592C (zh)
AR (1) AR019953A1 (zh)
AT (1) ATE243197T1 (zh)
AU (1) AU748177B2 (zh)
BR (1) BR9913357A (zh)
CA (1) CA2339007A1 (zh)
CO (1) CO5070576A1 (zh)
DE (1) DE69908951T2 (zh)
DK (1) DK1102747T3 (zh)
DZ (1) DZ3074A1 (zh)
EA (1) EA003205B1 (zh)
EE (1) EE04274B1 (zh)
ES (1) ES2200535T3 (zh)
FR (1) FR2782082B3 (zh)
HK (1) HK1035535A1 (zh)
HU (1) HUP0103134A3 (zh)
IS (1) IS5821A (zh)
MY (1) MY121447A (zh)
NO (1) NO320645B1 (zh)
NZ (1) NZ509561A (zh)
PL (1) PL345999A1 (zh)
PT (1) PT1102747E (zh)
SK (1) SK1742001A3 (zh)
TR (1) TR200100261T2 (zh)
TW (1) TW527354B (zh)
UA (1) UA72890C2 (zh)
WO (1) WO2000007987A1 (zh)
YU (1) YU8601A (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2023278843A2 (en) * 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
JP2000515534A (ja) * 1996-08-05 2000-11-21 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ ３，３―二置換ピペリジンの製造方法
US6040316A (en) * 1996-09-16 2000-03-21 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
NZ509561A (en) 2002-10-25
EP1102747B1 (fr) 2003-06-18
ES2200535T3 (es) 2004-03-01
HUP0103134A2 (en) 2002-06-29
FR2782082B3 (fr) 2000-09-22
MY121447A (en) 2006-01-28
EE04274B1 (et) 2004-04-15
US20040044215A1 (en) 2004-03-04
PL345999A1 (en) 2002-01-14
BR9913357A (pt) 2001-05-15
US7041679B2 (en) 2006-05-09
EA200100096A1 (ru) 2001-08-27
EP1102747A1 (fr) 2001-05-30
CN1314888A (zh) 2001-09-26
EE200100070A (et) 2002-06-17
KR20010072220A (ko) 2001-07-31
DZ3074A1 (fr) 2004-07-20
AU748177B2 (en) 2002-05-30
IS5821A (is) 2001-01-23
SK1742001A3 (en) 2001-11-06
EA003205B1 (ru) 2003-02-27
WO2000007987A1 (fr) 2000-02-17
ATE243197T1 (de) 2003-07-15
JP2002522419A (ja) 2002-07-23
YU8601A (sh) 2003-07-07
NO20010553D0 (no) 2001-02-01
NO320645B1 (no) 2006-01-09
DK1102747T3 (da) 2003-09-29
CN1114592C (zh) 2003-07-16
NO20010553L (no) 2001-04-05
CA2339007A1 (en) 2000-02-17
TR200100261T2 (tr) 2001-06-21
JP3807938B2 (ja) 2006-08-09
AR019953A1 (es) 2002-03-27
AU5168599A (en) 2000-02-28
DE69908951T2 (de) 2004-05-19
KR100571944B1 (ko) 2006-04-18
DE69908951D1 (de) 2003-07-24
CO5070576A1 (es) 2001-08-28
FR2782082A1 (fr) 2000-02-11
PT1102747E (pt) 2003-09-30
HUP0103134A3 (en) 2003-03-28
HK1035535A1 (en) 2001-11-30
UA72890C2 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
TW527354B (en) Crystalline forms of (R)-(+)-N-[[3-[1-benzoyl-3-(3,4dichlorophenyl)piperidine-3-y1]prop-1-y1]-4-phenyl piperidine-4-y1]-N-methyl acetamide (osanetant) and a process for preparing them
ES2391406T3 (es) Nueva forma cristalina V de la agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
JP5815765B2 (ja) イソオキサゾール誘導体及び代謝型グルタミン酸受容体ポテンシエーターとしてのその使用
JP7219213B2 (ja) （ｒ）－２－アミノ－３－フェニルプロピルカルバメートの溶媒和物フォーム
ES2208964T3 (es) Compuestos de pirrolilo substituidos para el tratamiento de la inflamacion.
KR100362295B1 (ko) 옥사졸리딘-2-온유도체
JP2004537597A5 (zh)
WO1996029326A1 (en) 3-benzylamino-2-phenylpiperidines as neurokinin antagonists
AR040500A1 (es) Inhibidores de cinasas
BRPI0111140B1 (pt) Forma polimórfica, uso da mesma, e, composição farmacêutica
JP2008508251A5 (zh)
EA004434B1 (ru) Кристаллическая форма ii линезолида
JPH05320142A (ja) 中枢神経系に薬理活性をもつ化合物
JP2014506602A5 (zh)
DE69019293T2 (de) Naphthyloxazolidon-Derivate.
Tarbell et al. The Synthesis of Some 7-Chloro-4-(3-alkylaminopropylamino)-quinolines1
US5055468A (en) Use of bridged tricyclic amine derivatives as anti-ischemic agents
ES2276281T3 (es) Compuestos con actividad en el receptor 5ht2c t sus usos.
JPS61280473A (ja) ３−フエニル−テトラヒドロピリジン誘導体及びその製造方法
PA8475401A1 (es) Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos
JP2004517088A5 (zh)
JP2000053824A (ja) β核剤を含むポリプロピレン組成物
IE67814B1 (en) Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases
JPWO2019241555A5 (zh)
DE2810143A1 (de) Aryl-alpha, alpha-bis eckige klammer auf omega- (disubstituierte amino) alkyl eckige klammer zu acetamide und deren saeureanlagerungssalze, verfahren zu ihrer herstellung sowie sie enthaltende arzneimittelzubereitungen

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees